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                                                        INTRODUCTION 
Leprosy or Hansen's disease  is a chronic actively  progressive  granulomatous 
disease caused by Mycobacterium  leprae, infectious in some cases and affecting the  
peripheral nerves , the skin  and certain other tissues  including  reticulo-endothelial 
system, bones and joints, mucous membranes, eyes, testes, muscles, adrenals, etc. Named 
after the Norway physician Gerhard Henrik Armauer Hansen, who discovered the bacilli 
first in 1873, Mycobacterium leprae is the first bacterium to be identified as a human 
pathogen and it is the only species of mycobacteria to infect peripheral nerves and 
specifically Schwann cells. 
Leprosy is an ancient disease, which has existed in our community for a longtime. 
Leprosy today is not the `Leprosy’ of yesterday – a far off, little understood disease, 
during its long course, there may occur acute bouts of exacerbation, generally called as 
‘Reactions’. 
Reactions are defined as `acute episodes occurring in an otherwise chronic course 
of infection’. It does not apply to the general progression or increase in the manifestations 
of disease. Remissions and relapse are the hallmark of reactions and these may last for a 
few weeks to few months.  
 
  Leprosy reactions are immunological phenomenon that occurs before, during or 
after the completion of multi-drug therapy (MDT). They contribute immensely to the 
burden of leprosy and need to be diagnosed and treated early to prevent nerve function 
impairment and permanent disability. 
  Reactions in leprosy are classified into Type-1 reaction, Type-2 reaction and 
Lucio phenomenon or Type-3 reaction .This study has been undertaken to determine the 
incidence and to study the clinical and histopathological features of lepra reactions in 
detail. 
                   
 
 
 
 
 
 
                      
 
AIM OF THE STUDY 
 
 
1. To study the incidence of different types of lepra reactions in various spectrum 
 of leprosy. 
 
2. To study the clinical & histopathological features of lepra reactions in detail. 
 
 
    
 
 
 
                       
REVIEW OF LITERATURE 
HISTORICAL ASPECTS OF LEPRA REACTION  
The word ‘Lepra’ was first used by Hippocrates (460-377BC) for a scaly skin 
condition The hebrew originals of the old testament books used ‘Tsaraath’ for number of 
scaly skin diseases [e.g summer  prurigo and psoriasis]  and the Greek equivalent ‘Lepra’ 
was later offered  in new testament work, thus the word ‘Lepra’ was applied. It could be 
said that the synonyms of modern leprosy may be ‘Lepra arabum’ and ‘Elephantiasis 
graecorum’.[1] 
Danielsson and Boeck (1848) and Hansen and Looft (1898) described a peculiar 
eruption in lepromatous leprosy, which resembled Erythema nodosum (EN) in its clinical 
appearance.[2]  A Japan leprologist Murata (1912), proposed the term ‘Erythema 
Nodosum Leprosum’ (ENL) based on the clear cut clinical and histopathological features. 
In 1939 Desouza Lima and Maurano had written that EN was the most frequent 
cutaneous symptom of lepra reactions. Desouza Lima and Desouza recorded the 
exacerbation of  leprosy reactions in patients on sulphone therapy, which were described 
as pseudoexacerbation for lack of better caption.[2] In 1942 Pecarno made particular 
attempt to delineate the difference between ENL and EN. 
Pogge and Ross (1946) stated in an article that “ leprosy is a chronic disease in 
which  there are atleast at times acute manifestation, the local lesion of which may be 
those of erythema nodosum or less often erysipeloid reaction of the skin, painful neuritis 
or painful lymphadenopathy’.  
In 1955 Wade H. W first used the term ‘ Reversal reaction’ to describe the 
appearance of skin lesion resembling those of tuberculoid morphology.[3] Tajiri (1955) 
reported a similar reaction as ‘acute lepromatous infiltration’. He also attempted to 
distinguish upgrading and downgrading reaction later.[4]  In 1959 W.H. Jopling 
introduced the terms Type I and Type II reaction and differentiated them.[5]  The term 
ENL has been in use for long time, since numerous symptoms occur in addition to ENL 
W.H.Joppling prefer the term Type 2 reaction.[6] 
A real breakthrough however was enacted by Ridley who based his observation on 
pathognomic histological abnormalities. He was the first to use the term upgrading 
reaction in 1969.[2] Wolcott R. R (1977) observed that the incidence of lepra reaction rose 
from 7% in the presulphone period to 93% in the post sulphone period. He emphasized 
the need for difference between simple progression of the disease and reaction.[2] 
Davidson A.R pointed out that higher the original bacteriological index, the more likely it 
was that ENL would develop. He concluded that ENL had a bad prognostic 
significance.[7] 
Type III lepra reaction was first described by Lucio and Alvarado in 1852. The 
eponoymic designation ‘Lucio phenomenon’ was first proposed by Latapi in 1948. It was 
Latapi and Zamora who brought the paper to the notice of the medical world.[8] 
                                                   LEPRA REACTION 
DEFINITION 
Lepra reactions are episodes of acute hypersensitivity to antigen of 
Mycobacterium leprae brought about by a disturbance in the preexisting immunological 
balance in leprosy patients. Clinically described by the appearance of symptoms and 
signs of acute inflammation in lesions of patients with leprosy.[1] 
Ridley defined ‘reactions’ as an apparent clinical and histological expression of an 
allergic inflammatory process, which essentially may not be part of infective process, 
either in its spread or resolution, though it may be associated with these phases.[2]  Ridley, 
Debi and Mohanty and Seghal et al defined ‘ reactions’ as acute episodes occurring in an 
otherwise chronic course of infection.[2] 
CLASSIFICATION 
Reactions in leprosy are incomprehensive both in concept and nomenclature. 
Various authors gave various classification at different times with different terminologies. 
Cochrane and Dharmendra classification [9] 
 
1. Reactions in tuberculoid leprosy and reactional tuberculoid. 
2. Reactions in dimorphous leprosy. 
 
 
3. Reactions in lepromatous leprosy. 
                - Erythema nodosum leprosum 
                - Progressive lepra reaction 
                - Lucio phenomenon or necrotic lepra reaction 
Hastings classification [1] 
1. Type 1 reaction associated with cell mediated hypersensitivity. 
2. Type 2 reaction associated with immune complexes. 
3. Lucio phenomenon associated with necrosis of arterioles whose endothelium is 
massively invaded by Mycobacterium leprae. 
 
Jopling W. H Classification [10] 
This classification was accepted at present. 
1. Type I Lepra reaction:-  Upgrading or reversal reaction  
                                        Downgrading reaction 
2. Type II Lepra reaction 
3. Type III Lepra reaction 
World health organization [WHO] has been using the term Reversal reaction (RR) for 
Type 1 reaction and Erythema nodosum leprosum for Type 2 reaction. 
 
                                                      
                                                 TYPE I REACTION 
SYNONYMS  -  [ Borderline reaction, Tuberculoid reaction, Reversal reaction, Jopling 
type 1, Coombs and Gell Type IV reaction, Non lepromatous lepra reaction ] 
INCIDENCE 
            In review of reaction, in the post multi drug treatment [MDT] era, Type I reaction 
was encountered in 11- 39 % of borderline tuberculoid [BT], 75- 100% of borderline 
borderline [BB], 15-44% of borderline lepromatous [BL], 2.4- 6.5% of lepromatous 
leprosy subpolar [LLs] and 3.8% of tuberculoid [TT].[11] Overall development of reaction 
at any time vary from 3.5% among pauci leprosy [PB] and 47.5% among multibacillary 
[MB] cases.[12] 
AGE 
           Type I reaction occur commonly in age group of 20 – 40 yrs. In children type I 
reaction are rare despite the high prevalence of leprosy in the form of Indeterminate or 
tuberculoid type.[13] 
SEX 
         Type I reaction occur in both sexes with equal frequency. Nerve damage is much 
more common in male patients with BT leprosy.[11] 
 
 
TIME OF ONSET 
80% of Type I reaction develop within 6 months of MDT. It can also occur even 
after 12 months to 2 years. Kumar et al reported that RR occurs most frequently during 6-
12months after starting MDT. Recurrent episodes of RR occurred within 3 months of 
stopping the course of prednisolone administered for the previous reaction.[14] 
TYPE I LEPRA REACTION ACROSS SPECTRUM OF LEPROSY 
Type I reaction are commonly seen in borderline spectrum of leprosy because of 
their immunological instability [i.e - BT, BB, BL]. Borderline patient may upgrade to TT 
to form secondary tuberculoid  [TTs] or it may downgrade to subpolar LL [ LLs ].[6, 15] 
PRECIPITATING FACTORS 
Upgrading reaction may be precipitated by [15, 16] 
1. Antileprosy treatment especially dapsone 
2. Pregnancy 
3. Postpartum state  
4. Lepromin testing 
5. Immunotherapy 
In BT, reversal reaction may occur spontaneously even before in taking the treatment.  
 
Downgrading reaction may be precipitated by [15, 16] 
1. Psychological stress 
2. Intercurrent infection – streptococcal, malaria, filarial, parasitic infestation 
3. Vaccination – Typhoid, TT, BCG. 
4. Malnutrition 
5. Pregnancy 
6. Other rare precipitating factors include hyperthyroidism,[17]  OC pills,[18]  
hormonal factors in puberty.[19] 
RISK FACTORS [11] 
     A recent study delineated the following risk factors 
1. Facial patch  
2. Enlarged ulnar nerve 
3. Positive Bacteriological Index [BI] 
4. Disease involving more than 2 body parts. 
5. Presence of antiphenolic glycolipid antibody in PB leprosy. 
CLINICAL FEATURES 
CUTANEOUS MANIFESTATIONS 
The most prominent sign is a rapidly developing change in the appearance of one 
or all the skin lesions, the existing lesions become erythematous, edematous, raised with 
distinct edge, more prominent, warm to touch, tender and resembling erysipelas. Similar 
new lesions can occur in crops but unusual. Lesions resolve with desquamation and 
scaliness and flattened later to form wrinkled surface. Sometimes they may ulcerate and 
heal with scarring. Another manifestation is edema of the involved site. It can occur over 
hands, feet or face either independently or together. Tenderness of palms and soles are 
sometimes present.[20] 
Dogra et al [2004] reported a case of BL Hansen disease in Type I reaction 
presented as phimosis.[20] Gupta et al reported a case of erythematous infiltrated plaque 
over scrotal skin in a 4yr old child diagnosed as BL in Type I reaction.[21] A case report of 
lepra reaction presenting as acute polyarthritis in the setting of Type I downgrading 
reaction has been reported by a rheumatologist.[22] 
NEURITIS 
It is the most important component of Type I reaction. It may occur independently 
or together with skin changes. Most common in males with BT Hansen. Clinically 
manifest as neural pain at the site of predilection and the pain may refer to the region of 
skin it supplies. Nerves are thickened and tender on palpation. There may be acute loss of 
function resulting in  both  sensory or motor paralysis.  Anesthesia or extent of anesthesia 
develops rapidly in the region of distribution of the affected nerve. Sudden paralysis of 
the muscles of hand, foot or face occurs as claw hand, wrist drop, foot drop and facial 
palsy including lagopthalmus. Rarely nerve abscess forms producing fluctuant tender 
swelling. Nerves at risk for paralysis are ulnar nerve, lateral popliteal nerve and facial 
nerve.  Nerve abscess are commonly seen in ulnar nerve, greater auricular nerve and 
lateral popliteal nerve. Sometimes, nerve function may get affected without any pain or 
tenderness of the nerve or inflammation of skin lesions.  Van Brakel and Khawas 
proposed the term “Silent neuropathy (SN) /Quiet nerve paralysis’’ to describe this 
phenomenon of nerve function impairment occurring in the absence of symptoms.[23]                       
Systemic disturbances such as fever, malaise, are unusual, seen only in severe 
reaction. Tenosynovitis of extensor tendon over back of wrist may develop during Type I 
reaction. 
GRADING OF TYPE I REACTION 11 
There are three grades to access the severity of Type I lepra reaction. 
MILD – erythema, swelling and tenderness of existing lesion / a few lesions may appear. 
MODERATE – erythematous patches/ plaques with effusion of joints / edema of limbs. 
SEVERE – numerous inflamed lesions that may ulcerate with painful neuritis causing 
paralysis. 
COMPLICATIONS 
1. Sudden onset of paralysis resulting in claw hand, foot drop, wrist drop or facial 
paralysis. 
2. Ulceration of skin lesion 
 
HISTOPATHOLOGY [1,6] 
In acute stages, there is profound dermal edema which causes disorganization and 
dispersal of the granuloma. In upgrading reaction, there is increased number of defensive 
cells such as lymphocytes, formation of giant cells and small cluster of epitheloid cell and 
decrease in number of bacilli. In downgrading reaction, defensive cells are replaced by 
macrophages and there is increase in number of bacilli. In severe reactions, necrosis may 
occur in small foci or sometimes causing liquefaction of the entire granuloma, there may 
be fibrinoid necrosis and finally fibrosis. 
 
IMMUNOLOGY AND PATHOGENESIS 
Type I reaction is a delayed hypersensitivity reaction [Gell and Coombs type IV 
hypersensitivity] in which cell mediated immunity plays the major role. It occurs as a 
result of interaction of T lymphocytes with antigens liberated from M. leprae. On break 
down of microorganism two portions of antigen are released. The protein fraction elicits 
the cell mediated immunity and polysaccharide portion elicit a humoral immunity.[6] 
These antigens react with T lymphocytes and on T cell activation Th1 mediated cytokines 
IL-2, IFN-γ and TNF-α are released.  
These inflammatory cytokines are thought to be responsible for nerve damage.[24] 
Pro-inflammatory cytokines IL-6, IL-10, IL-13 are also released and  have number of 
effects within the granuloma including promotion of protective cellular response, 
maintenance of granuloma formation and initiation of nerve damage.[25,26,27] The presence 
of both  pro and anti-inflammatory cytokines highlight the multiplicity of cytokine 
expression within the granuloma and suggest Th1 cell mediated immune response plays a 
role in reactional pathology.[25] 
Normally during leprosy a delicate balance exists between the antigen available 
for immune reaction and host response. Any alteration of the balance induces a reactional 
state. Any change in the immunological status brings about a shift in the clinical 
spectrum of leprosy. The various shift across the leprosy spectrum are LL -> BL -> BB    
-> BT -> TTs.[2] Lepromatous leprosy polar [LLp] and tuberculoid polar [TTp], the polar 
forms are immunologically stable. The reverse occur in downgrading reaction BT -> BB   
-> BL -> LLs.[6] 
In reversal reaction there is a progressive increase in CMI and destruction of 
bacilli. RR can occur either spontaneously or during and after completion of treatment. 
Sometimes it may occur long after the treatment or cessation of lesions. The longest 
period reported so far is 16 years after release from treatment [RFT].[28]  They are called 
as late reversal reaction. Late reactions is known to occur mostly within first 3 to 4 years 
after RFT. This was explained by the possible mechanism that persisters in inaccessible 
area escape from organic defence and drugs, often go for multiplication when conditions 
are favourable due to intercurrent illness or immunological changes.[29] 
            Shetty et al  who studied 25 patients of BT leprosy, some of who presented with 
late RR occurring 1-13 years after MDT.[30] Patients with low bacilli count resolved 
completely as the body defense are able to deal with them. And those with high number 
of bacilli new reactions, nerve damage and disability are common. 
The activation of T cells in case of RR is evidenced by 10 fold increase of IFN-γ 
in lesions of RR. In another study 4 fold increase of human gene serine factor [huHF] a 
marker of cytotoxic cells was observed. Also observed are increased levels of neopterine 
at the onset of RR and its decline after steroid therapy.[31] There is also increased 
conversion of lymphocytes to lymphoblast and increase in Langerhans cells in the 
skin.[11] This immunological upgrade can be evidenced by a previously negative lepromin 
test becoming positive.     
In downgrading reactions there is decrease in CMI and increase in the number of 
bacilli. This occurs when the patient is not on treatment. The continuous multiplication of 
the bacilli leads to overwhelming of antigen resulting in immune paralyses and cause 
downgrading reactions. This is evidenced by previously positive lepromin test becoming 
negative.    
DIAGNOSIS 
The diagnosis is mainly clinical. In Type I reaction it may sometimes difficult to 
differentiate RR and downgrading reactions. The following investigation may be helpful 
in differentiating them. 
1. Lepromin test 
2. Skin biopsy 
3. Lymphocyte transformation test 
4. Lymphocyte stimulation test 
      DIFFERNCE BETWEEN REVERSAL AND DOWNGRADING RAECTION 
  
REVERSAL REACTION 
 
DOWN GRADING 
REACTION 
RELATION TO 
TREATMENT 
 
Occur while on taking 
treatment. 
 
Occur without  treatment / 
on irregular / default 
treatment. 
CHANGE IN EXISTING 
SKIN LESION 
 
Well defined and more 
prominent / no change in 
all lesion. 
 
No marginal definition / 
appear less prominent / 
changes in all lesion. 
 
NEW LESION 
 
No new lesion 
 
More new lesion 
 
NEURITIS 
 
 
No new nerve damage/ 
already involved may be 
inflamed. 
 
New nerve  involvement 
occurs. 
 
BACTERIOLOGICAL 
INDEX 
 
Decreases 
 
Increases 
LEPROMIN TEST 
 
Negative reverts to 
positive. 
 
Positive become weakly 
positive or negative. 
HISTOPATHOLOGICAL 
FEATURES 
 
Defensive cells such as 
lymphocytes, epitheloid 
cells / increased giant cells 
/ fibrosis present / bacilli 
decreased. 
 
Defensive cells are replaced 
by macrophages / no fibrosis 
/ bacilli increased. 
 
COURSE AND 
PROGNOSIS 
 
Subsides in few weeks / 
relapse uncommon. 
 
Prolonged course / 
recurrence more common. 
 
 
DIFFERENTIAL DIAGNOSIS 
1. Erysipelas 
2. Urticaria 
3. Relapse of Hansen 
DIFFERENCE BETWEEN REVERSAL REACTION AND RELAPSE 
    REVERSAL REACTION             RELAPSE 
Occurrence Occur in BT, BB, BL, LLs 
type of leprosy. 
Occur in all types and 
subtypes of leprosy. 
Onset  Sudden. 
Within 6months – 2yrs of 
termination of treatment. 
Insidious. 
After 1-5yrs of termination 
of treatment. 
Clinical features Erythema and edema of 
existing lesions appear. 
Similar new lesions occur. 
Edema of hands and feet 
present. 
Old lesion show slow 
extension in areas with 
increase signs of activity. 
New lesions appear . 
Edema not prominent. 
Nerves Previously involved nerve 
tender and detoriate with 
sensory or motor defecit. 
Nerve abscess occur 
Fresh nerve involvement. 
Sudden paralysis not seen. 
Nerve abscess not seen. 
 
SSS Usually Negative. Positive in BL, LL relapse. 
Negative in TT relapse. 
 
Response to steroid 
 
Respond well within 2 
months. 
 
Disease progressive. 
COURSE AND PROGNOSIS [9] 
Upgrading reaction is usually a temporary condition and subsides in a few weeks. 
Relapse are uncommon, the acute exacerbation often influence the prognosis favorably. If 
the reaction is severe, it may result in permanent nerve damage with consequent 
deformity. Downgrading reaction run a prolonged course and recurrence are more 
common. 
                                                  TYPE II REACTION 
SYNONYMS :- [ Roseolar leprosy, Jopling type II, Erythema nodosum leprosum, ENL 
syndrome, [6]  Lepromatous lepra reaction, Coombs and Gell type III , Lepra Fever, Acute 
exanthem of leprosy. [32]] 
INCIDENCE 
 Overall incidence of ENL reported to occur in 50% of LL and 25% of BL in the 
pre MDT era. In post MDT era it has fallen to 12% in LL and 2.1% in BL.[14] Occur in 
about 35% of patient with LL33 and 3.1% of pediatric patient with LL.[34] 
AGE 
          Type II reaction occurs mainly in age group 20 – 40 years. The highest incidence 
of ENL reactions has been noted between 11- 40 years, corresponding to the highest age 
incidence of leprosy in South India.[35] 
SEX 
        Type II reaction occurs in both sexes with almost equal frequency showing some 
predominance in males. A study of ENL cases in South India had attributed the male 
predominance to the high proportion of male patients attending the hospital.[35] Browne 
had reported high incidence among males.[36]  Guinto reported high incidence in 
female.[37] 
TIME OF ONSET 
50% of ENL reactions occurred in the 2nd or 3rd year after starting MDT. Reaction 
continued to occur up to 8 years after RFT. Kumar et al reported   that ENL occur mostly 
during 2nd or 3rd year after starting MB MDT.[14] 
ENL may present as denovo at first visit. A publication from Los Angeles reported 
a series of 32 adults presenting with reaction for first time and 69% had ENL.[38] In a 
study reported from India 40% of LL patients presented with ENL at the first visit.[39] 
The overall incidence of recurrent ENL was 64.3% and manifest 5 or more 
episodes over a period of 2 years. Transaction of 16th International Leprosy Congress 
labeled ‘chronic ENL’ if the patient needs continued antireaction treatment for a period 
of more than 6 months.[14] 
 
 
TYPE II REACTION ACROSS SPECTRUM OF LEPROSY 
Type II reaction occurs only in lepromatous form of leprosy [ie BL, LLs, LLp]. 
50% of LL and 25% of BL can suffer from Type II reactions.[14] Previously Histoid 
Hansen was thought not go in for ENL. But more recently ENL has been reported in 
Histoid Hansen.[39, 40] 
PRECIPITATING FACTORS [6, 14] 
1. Psychological  stress 
2. Physical stress and injury 
3. Surgery 
4. Physiological stress – menstruation, pregnancy, parturition, puberty 
5. Intercurrent infection – malaria, filarial, chicken pox, typhoid 
6. Drugs – dapsone, sulphonamide, thioacetazone, rifampicin, iodides, bromides 
7. Seasonal variation – Murata reported ENL more common during summer or 
autumn. 
8. Others - ingestion of alcohol/ hot foods/ mantoux testing/ vaccination. 
RISK FACTORS [14, 41] 
1. Female gender 
2. Higher BI > 3 
3. HIV 
4. Pregnancy and lactation 
CLASSIFICATION OF TYPE II REACTION[42] 
Based on mode of onset of reaction ENL are classified as  
1. Rheumatic type -  start with fever and joint pain and later develop skin lesion. 
2. Exanthematous type – start with fever and skin lesion simultaneously. 
3. Mixed type - start with fever, joint pain and skin lesion simultaneously. 
CLINICAL FEATURES [9] 
CUTANEOUS MANIFESTATIONS 
ENL lesions are most characteristic cutaneous lesion of Type II. They occur as 
crops of erythematous, evanescent [lasting only for 2- 3days], painful, slightly raised, 
dome shaped nodules; ill-defined in margin measuring few mm to cm, blanches on light 
finger pressure. They tend to appear more in the evening [at time when endogenous 
corticosteroid production is at its lowest]. They occur more commonly on face, arms and 
distributed bilaterally and symmetrically, not superimposed on old leprosy lesion. They 
resolve with desquamation and scaling leaving behind a bluish stain in the skin. 
Recurrences occur at the same site.  
The classical lesions are papules, nodules and plaques. Apart from classical ENL 
Type II reaction can also manifest as vesicular, bullous, hemorrhagic, pustular, ulcerated 
and EMF like lesions.[43] Bullous type of ENL cases have been reported from Mexico, 
South India and Nepal.[44] 
Pustular and haemorrhagic ENL carry poor prognosis.[42] Pustules contain sterile 
pus with polymorphonuclear leukocytes and degenerated bacilli. Erythema necroticum 
ulcerans has been reported in adults and rarely in children barring one case report by 
Pandhi et al.[34]Pretibial ulceration also reported in Type II reaction.[42]                                                      
NEURITIS 
          Neuritis are less common and less dramatic in Type II reaction when compared to 
Type I reaction. Only in severe reaction nerve become enlarged, tender and lose function 
rapidly. 
CONSTITUTIONAL SYMPTOMS 
ENL is usually accompanied by generalized systemic illness which manifest in the 
form of fever, malaise, headache, anorexia, insomnia and depression. The fever is usually 
intermittent, high grade, high in the evening and associated with chills and rigor. Edema 
of hands, feet, face and painful dactylitis are other general manifestations of Type II 
reaction. 
SYSTEMIC MANIFESTATION 
EYE 
          Ocular manifestation includes iritis, episcleritis, iridocyclitis, conjunctivitis, 
keratitis, lagophthalmos and secondary glaucoma. Most dreaded among them is 
iridocyclitis. It manifests as redness, diminished vision, photophobia, epiphora and ocular 
pain. Any delay in treatment of  iridocyclitis, may result in irreversible blindness. 
A case of Orbital apex syndrome describing the orbital involvement due to ENL 
has been reported. Dhaliwal et al described the involvement of left maxillary and ethmoid 
sinus along with destruction of medial orbital wall associated with vasculitis.[45] 
ENT 
          ENL lesions can involve the mucus membrane of nose, mouth, pharynx and larynx. 
It may result in rhinitis, epistaxis, nasal blockage, difficulty in breathing, erosion, 
ulceration and perforation of nasal septum. 
MUSCULOSKELETAL 
         Myositis and arthritis are common manifestations in Type II reaction. ENL lesions 
extending to the fascia and muscle produce tender, woody hard lesion on the muscle 
particularly seen in brachioradialis. Multiple ENL nodule with inflammatory edema 
along with arthritis of interphalangeal joint constitute a condition known as ‘The 
Reaction Hand’.  
Arthritis in Type II reaction are of rheumatic type and commonly affects knee, 
metacarpophalangeal joint, inter phalangeal joint, wrist and ankle. It manifest as painful 
warm joint swelling with limitation of movements. The joint manifestations are inversely 
proportional to the skin lesion. 
 Dactylitis is an another feature in Type II reaction manifesing as painful spindle 
shaped swelling of the phalanges. Periostitis and osteoporosis are other manifestations of 
Type II reaction affecting mainly the long bones, tibia and phalanges.  The radiological 
findings include soft tissue swelling, osteoporosis, subarticular collapse, pseudo cyst [as 
punched out area of rarefaction], ankylosis and disorganization. 
LYMPHADENITIS 
            Half of Type II reaction cases shows lymphadenitis. Preauricular lymphadenitis 
precedes the onset of lepra reaction and it is a premonitory sign in Type II. Other groups 
involved are cervical, axillary, intercostal and inquinal nodes. Initially they are discrete, 
later become matted and sometimes go for necrosis or suppuration. 
EPIDIDYMO-ORCHITIS                                                                                                                        
            Its one of the important manifestations of Type II reaction. It may be unilateral or 
bilateral. May be acute with painful swollen testis that atrophies quickly. Gyanecomastia 
usually follows testicular atrophy. Acute mastitis can occur in females as a result of Type 
II reaction. 
OTHER SYSTEMS  
            Pleuritis can occur as respiratory system manifestation. Hepatitis which is 
reversible may occur and sometimes it may lead to persistent hepatomegaly, ascites and 
hepatic amyloidosis. Renal involvement may manifest as glomerulonephritis causing 
haematuria, oliguria and sometimes lead to renal amyloidosis. Cardiovascular changes 
with low BP and pericardial friction rub has been reported. The occurrence of leprous 
vasculitis and leprous meningiovasculitis has been reported in lepra reaction. 
GRADING OF TYPE II LEPRA REACTION [42] 
MILD – Temperature up to 100o F and a few skin lesion on one or more extremities. 
MODERATE - Temperature up to 102o F, skin lesion are more numerous in all four 
limbs and few on the trunk and face with occasional vesicle and pustule. Extra cutaneous 
signs present. 
SEVERE – Temperature above 102oF, vesiculation and pustulation present. Visceral 
involvement present. 
COMPLICATIONS 
1. Paralysis of involved nerves 
2. Ulceration of skin lesions 
3. Blindness 
4. Infertility 
5. Perforation of nasal septum and hard palate 
6. Secondary amyloidosis 
7. Debility and exhaustion 
 
 
HISTOPATHOLOGY [1,6] 
In skin, pathology is seen in deep dermis or subcutis. At the onset it is 
characterized by edema of papillary dermis, sharp influx of neutrophils and lymphocytes. 
Mixed dermal inflammatory infiltrate composed of neutrophils and lymphocytes 
superimposed on collection of foamy macrophages containing fragmented bacilli. 
Neutrophilic leucocytoclastic vasculitis affecting the arterioles or venules is a significant 
feature with endothelial swelling and intense infiltration of polymorphonuclear 
leucocytes around blood vessel. Scanty fragmented and granular bacilli are seen around 
the vessels. Extravasated erythrocytes are often seen. The subcutis shows mixed lobular 
and septal panniculitis. DIF reveals deposition of Ig G and C3 in the walls of dermal 
vessels. 
In erythema necroticans, involvement of superficial dermis and epidermis with 
ulceration, in addition to vasculitis and necrosis  are seen. In bullous ENL intraepidermal 
cleft with diffuse polymorphonuclear infiltrate and few foamy histiocytes along with few 
AFB.[44] In addition to skin, the reacting granuloma may be found in nerves, lymphnodes, 
liver, muscle and synovium. 
 
 
 
IMMUNOLOGY AND PATHOGENESIS  
Type II reaction is an immune complex mediated syndrome [Coombs and Gell 
type III hypersensitivity reaction] where the humoral immunity plays the major role. 
Large amount of M. leprae antigens are available both intracellularly and extracellularly 
after release from the macrophages. The pathogenesis of release of antigen is not fully 
understood but suggested as an immunological process. The polysaccharide portion of M. 
leprae is responsible for elicitation of humoral immune response. These antibodies cross 
react with cardiolipin and antigen of many different organs. The released mycobacterial 
antigens combined with antibodies get deposited as immune complex along vulnerable 
capillaries of skin, synovial membrane and glomeruli. Complement is activated by 
immune complexes and attracts neutrophils which release lysozomal enzymes resulting in 
tissue damage. 
It has been recently observed that these antibodies are of mainly Ig G3 subclass 
and it react with distinct motifs R.G.D [arginine, lysine, aspartic acid] which bind to 
fibronectin receptors of macrophages.[11] Wenambu et al found that Ig and C are present 
only in early ENL lesions and in ENL lesions examined after 24 hours, they found no 
such deposits in their lab animal experiment.[46] 
Patnaik et al reported that immune complex mediated mechanism is responsible 
for the exudative lesion seen in hepatic morphology during ENL. The eyes, renal and 
joint manifestation of ENL are attributed to immune complex mediated mechanism.[47] 
ENL is associated with a strong Th2 response with high expression of IL- 4, IL-5, 
and  IL-10. TNF - α concentration in blood also rises to very high levels leading to 
systemic manifestation like fever. It has also been noted that there is increase CMI to M. 
leprae antigen in ENL reaction with increase in number of T cell and increase in CD4 /  
CD8 ratio up to two fold. It was observed that there is decrease in CD8 T cells and 
cytotoxic T cells in ENL lesion. This decrease in CD8 T cells may induce a change in 
amount and affinity of antibodies which favour the formation and deposition of immune 
complex. 
Mshana et al pointed out the failure to excite arthus reaction on intradermal 
injection of M. leprae antigen into a LL patient.[48] Another phenomenon observed in 
ENL lesion is a significant increase in apoptosis observed at 6 months of treatment.[49] 
Oliveria and colleagues found apoptosis to be greatly accelerated in circulating 
neutrophils in patients experiencing ENL.[50] 
The other serological abnormalities observed during Type II reaction includes 
positive for autoantibody such as RA factor / ANA. IgG, IgM, C2, C3 and CRP are also 
increased during the acute phase. 
DIAGNOSIS 
1. Mainly clinical. 
2. Abnormalities in other laboratory  investigations includes         
 
 Hematological  
1. Leukocytosis 
2. Thrombocytosis 
3. Raised ESR 
4. Normocytic normochromic anemia 
5. Profound fall in Hb% and erythrocytes count [severe reaction]. 
      Biochemical 
1. Abnormal LFT showing increase in SGPT. Increase in Serum bilirubin occurs 
during hemolytic crisis in severe reaction. 
2. Alteration of albumin to globulin ratio is another biochemical change reported 
mainly by increase in α-globulin. 
      Skin biopsy and histopathology 
      DIF – shows deposits of Ig G and C3 in the vessel wall. 
DIFFERENTIAL DIAGNOSIS [DD] 
DD for Classic ENL 
1. EN lesions due to other causes like TB, CTD should be excluded. 
2. Panniculitis secondary to infection, malignancy, vasculitis, Weber Christian 
disease. 
 
DIFFERENCES BETWEEN ENL AND EN 
 ENL EN 
Numbers  Numerous  Less in number 
Site  All over the body including 
face. 
Limited to legs. 
Nature of lesion  Evanescent, may ulcerate. No evanescence, never 
ulcerate. 
Diurnal variation Appears usually in evening. No diurnal variation. 
Histopathology  Septal panniculitis with 
foamy macrophages 
containing degenerated 
AFB in the dermis. 
Septal panniculitis with 
dermis showing 
perivascular lymphocytic 
inflammatory infiltrate in 
early lesion and lipid laden 
macrophages in late lesion 
with no AFB.  
 
 
DD for bullous and pustular ENL 
1. Erythema multiforme 
2. Varicella 
3. Pemphigus vulgaris 
4. Bullous pemphigoid 
5. Pustular psoriasis  
 
                                           TYPE III LEPRA REACTION 
SYNONYMS: - [ Lucio phenomenon, Lepra manchada ] 
This type of reaction is confined to the diffuse non nodular form of LL chiefly 
encountered in Mexicans. This was first described by Lucio and Alvarado in Mexico 
[1852]. The unique feature is that it is seen only in untreated patients. 
CLINICAL FEATURES 
Painful and tender red patches appear on the skin, particularly on the extremities. 
They become purpuric, the centre of the purpuric lesions becomes necrotic and ulcerated 
and finally develops a brown or black crust [eschar] which falls off after a few days 
leaving a superficial atrophic scars. Lesions most commonly occur on the legs and less 
commonly on thighs, forearm and buttocks. Trunk and face are usually spared. Few 
lesions appear as bulla and burst to leave deep ulcers with jagged edges which heal 
slowly. Rea and Leavan in their study found that Type III reaction patients were afebrile 
throughout the course of reaction.[51] 
COMPLICATION 
1. Secondary pyoderma and cellulitis. 
2. Secondary amyloidosis. 
 
 
HISTOPATHOLOGY 
Type III lepra reactions are histopathologically characterized by 
1. Ischaemic epidermal necrosis. 
2. Necrotizing vasculitis of small blood vessels in the upper dermis. 
3. Severe focal endothelial proliferation of mid dermal vessels. 
4. Presence of large number of bacilli in the endothelial cells.  
IMMUNOLOGY AND PATHOGENESIS 
The immunology of Lucio phenomenon is believed to be based on Sanarelli 
Schwartzman reaction [non allergic but hypersensitivity phenomenon] where the basic 
pathology is due to unhindered multiplication of M. lepra in the vascular endothelium.[52] 
The exposure of the bacterial antigen to the circulating antibodies results in vasculitis, 
infarction and necrosis. 
If the patient with Lucio phenomenon are given a lepromin test, they usually 
develops extensive local reaction [the Medina – Ramirez reaction] occurring within 4 -6 
hrs and is a reproduction of the lesion in Lucio phenomenon.[19] Other immunological 
abnormalities seen in Lucio phenomenon are hypergammaglobulinemia, mixed 
cryoglobulinemia and positive VDRL test for syphilis. 
 
 
LABORATORY INVESTIGATION 
The usual laboratory findings are leukocytosis or absolute neutrophils, anemia, 
high ESR, hypergammaglobulinemia and positive cardiolipin antigen test for syphilis. 
DD for ulcerative skin lesion 
1. Ecthyma 
2. Pyoderma 
3. Ischemic ulcers 
4. Intra vascular coagulopathy 
5. Deep mycosis 
6. Lymphocytoma cutis 
DD for purpuric lesions 
1. Henoch Schoenlein Purpura 
2. Pityriasis lichenoides et varioliformis acuta [PLEVA] 
3. Cutaneous allergic vasculitis 
 
 
 
 
                                   MANAGEMENT OF LEPRA REACTIONS 
Four principles that need to be considered in management of reactions are [53] 
1. Control neuritis in order to prevent anesthesia paralysis and contracture. 
2. Halt damage to eye preventing blindness. 
3. Control the patients pain. 
4. Kill bacilli and stop disease progression. 
Depending  on these principles four aspects of treatment are given as follows 
1. Anti-inflammatory therapy primarily to reverse nerve damage. 
2. Analgesia to control the patients’ pain. 
3. Physical measures to prevent or reverse contracture. 
4. Antibacterial therapy of disease itself should be continued. 
GENERAL MEASURES COMMON TO TYPE I AND TYPE II REACTION 
1. Mild cases may be treated as ambulatory cases but severe cases must be 
hospitalized and complete bed rest should be reserved for those with impending 
motor palsies. 
2. To relieve anxiety and mental stress a tranquilizer or sedative may be prescribed 
and antibiotics are added if intercurrent infection present as precipitating factors. 
3. To alleviate the pain NSAID, aspirin [200 – 600 mg 4 to 6 times daily], ibuprofen 
[200 -400mg tds] or indomethacin [25 – 50mg bd / tds] can be given. 
4. Reassurance and counseling are particularly important because patient thought that 
he is not responding to treatment instead getting worse. This may make them to 
discontinue the anti-leprosy drugs. They can be assured that they are recovering 
the lost immunity and the disease is getting eliminated. 
MANAGEMENT OF TYPE I REACTION 
Anti-Leprosy Treatment should be continued. If the patient is on dapsone at time 
of reaction it is continued at its full dose and if he is not on dapsone at the time of 
reaction it can be started after the reaction is brought under control. 
CORTICOSTEROIDS  
This is the mainstay of reaction management. In 1950, Chaussinand first 
mentioned about the use of cortisol / ACTH in the treatment of Type I reaction. 
Thereafter it was brought into use for both Type I and II reactions. 
Mechanism of action 
1. Suppresses both early and late phase of inflammation. 
2. Normalizes disturbed T4 : T8 ratio. 
3. Causes suppression of T cell driven inflammatory response to M. leprae antigen. 
 
 
WHO steroid regimen for Type I reaction. Tablet prednisolone should be taken  once 
daily in the morning as follows, [54] 
40 mg - 2weeks 
30 mg - 2weeks 
20 mg - 2weeks 
15 mg - 2weeks 
10 mg - 2weeks 
5 mg   - 2weeks 
Treatment proposal by Ben Naafs  is as follows,[55] 
  Paucibacillary                                                   Multibacillary 
40 mg – 2 weeks                                               30 mg – I month 
30 mg – 2 weeks                                               25 mg – 2 months 
25 mg – 1 month                                               20 mg – 3 months 
20 mg – 2 months                                             15 mg – 2 months 
15 mg – 1 month                                               10 mg – 2 weeks 
10 mg – 2 weeks                                                 5 mg – 2 weeks 
5 mg   – 2 weeks 
Total   – 6 months                                               Total – 9 months 
 
Generally most BT patients require prednisolone for 4 – 9 months, BB patient for 6 – 9 
months and BL patients for 6 – 18 months or even for 24 months.[1,6] Side effects of 
steroids includes HT, DM, osteoporosis, peptic ulceration, Cushing syndrome, cataract, 
glaucoma, reactivation  of latent infection [such as TB], drug dependence, muscle 
wasting, etc. 
So monitoring is considered very important by taking into account the following 
parameters 
1. Monitor BP and weight at each visit. 
2. Urine analysis and blood sugar estimation. 
3. Gastric protection with H2 blockers or proton pump inhibitors. 
4. Osteoporosis prevention. 
CLOFAZIMINE [LAMPRENE] 
Less useful in Type I reactions especially in RR. This red immunophenazine dye 
was first discovered by Dr. Vincent Mary and it was Dr. Stanely Browne who first used it 
clinically in leprosy. It is useful in reaction because of its anti-inflammatory property. 
Mode of action [5,6] 
1. Decreases neutrophilic chemotaxis to the inflamed area. 
2. Decreases antibody formation. 
3. Increases synthesis of lysozomal enzymes and enhance phagocytic ability of 
macrophage resulting in complete digestion or degradation of antigens to less 
antigenic form. 
Clofazimine acts very slowly and take weeks for its full effect. So it has limited role in 
neuritis. 
Dose: - Initial -> 300 – 400 mg/day then gradually tapered and maintained in dose of 100 
mg/day. 
Side effects include reddish brown pigmentation of the skin, conjunctiva, body secretion, 
faeces, cornea and retina, icthyosis, pruritus, photosensitivity and eosinophilic enteritis. 
 
MANAGEMENT OF NEURITIS 
Various treatment modalities for neuritis includes 
1. NSAIDS. 
2. Anti reactional drug – corticosteroids helps in dispersion of intra neuronal edema. 
3. Supportive therapy in form of padded splint. 
4. Sessions of graduated passive and active exercises to prevent joint stiffness and to 
aid muscle recovery. 
5. Intra neural injection – a combination of 1 ml of 2% lignocaine, 1 ml of 
hydrocortisone and 1500 units of hyaluronidase are injected into swollen nerve or 
around the nerve using 14 size needle. 
6. Surgical treatment – Nerve decompression [ neurolysis ], decompression with 
transposition or with epicondilectomy. 
 
 
 
 
MANAGEMENT OF TYPE II REACTION 
WHO expert committee discussed the management of Type I reaction and ENL 
together, advising a 12 week steroid regimen and proposed severe ENL can be treated 
with prednisolone a 12 weeks course with the maximum dose  not exceeding 1mg / kg 
body wt.[54] 
ILEP technical bulletin recommends treating severe ENL with corticosteroid at a 
starting dose of 30 – 60 mg and reducing every week by 5 – 10 mg. It also states that a 
maintenance dose of  5-10 mg may be needed for several weeks to prevent recurrence.[57] 
Various other drugs used in ENL are as follows 
1. Anti-inflammatory drugs, aspirin [400mg 6 hourly] and indomethacin [50mg        
8 hourly] can be used in mild cases of ENL. 
2. Chloroquine - It is used in mild & moderate ENL cases due to its anti-
inflammatory property. It is given in the dose of 250 mg tds for 1 week, 250 mg 
bd for 2nd week and 250 mg once daily thereafter. Side effects like visual 
disturbance limit its use. 
3. THALIDOMIDE 
               It is highly effective in acute severe and recurrent ENL. In 1965 Sheskin 
reported the effectiveness of thalidomide in the management of ENL. It is a racemic 
glutamic acid analogue composed of 2 enantoimers R- and S- Thalidomide. These 2 
enantoimers have different properties; one is a potent suppressor of TNF release while 
the other is sedative. 
Mode of action 
           - Inhibits the release of TNF, IFN- α, IL-10, IL-12 and NF κB.  
           - Decreases the effect of complement derived chemotactic factors resulting in 
              reduction and non-recruitment of PMNL into the lesional site. 
Side effects include teratogenicity, drowsiness, sedation, irreversible peripheral 
neuropathy, constipation, etc. WHO committee advises that it should be given only to 
men or post-menopausal women who are dependent on corticosteroid.[54] 
4. Clofazimine is indicated in Type II reaction in the following situation 
                - In patients who cannot be weaned off from steroids. 
                - In patients who are troubled by continuous ENL. 
                - Where thalidomide is not available or cannot be used 
In severe recurrent chronic ENL pulsed i.v corticosteroid monthly once along with 
azathioprine 50mg daily can be tried as suggested by Mahajan et al.[58] 
MANAGEMENT OF TYPE III REACTION 
Mild cases - self-limiting. 
Moderate and severe cases - Steroids are moderately effective. Thalidomide, clofazimine 
and other immunosuppressant are ineffective. Plasmapheresis is reported to be effective. 
OTHER DRUGS IN LEPRA REACTION [56] 
ANTIMONIALS - Potassium antimony tartrate and Stibophen were used in Type II 
reaction and mild Type I reaction. Since they are less effective and more toxic, less 
frequently used nowadays. 
COLCHICINE- It has been found to be useful in recurrent severe ENL in dose of 1.5 – 
2mg daily in divided doses. It is used in ENL for its ability to inhibit neutrophilic 
chemotaxis. 
NON STEROIDAL IMMUNOSUPPRESSANTS 
Azathioprine – it acts by decreasing the synthesis of TNF-α. It is effective in severe or 
refractory ENL in recommended dosage of 50mg / day.[59] 
Mycophenolate mofetil – useful as steroid sparing agent and in patients in whom 
systemic steroids are contra indicated. It acts by inhibiting type II Inosine 
Monophosphate Dehydrogenase expressed in activated T and B lymphocytes resulting in 
induction of apoptosis of activated T cells and elimination of clones of cells.[60] 
Methotrexate – useful in severe and refractory ENL.  
Cyclosporine A – It is potent immunosuppressant shown to suppress activation of T 
helper cells, reduce IL-2 receptors and inhibit IL-2 production. Its role in ENL thought to 
be promising but relevant data are lacking.  
PENTOXYPHYLLINE - used in Type II reaction because of its immunomodulator 
effect.[61] 
LEVAMISOLE - It is considered in reaction for its ability to restore T cell numbers to 
normal. 
ZINC - It is recommended in treatment of necrotic ENL and chronic leg ulcer in dosage 
of 220mg tds. It did its role by inhibiting neutrophilic chemotaxis and complement 
mediated reaction. This is still under extensive trial.[62] 
PLASMAPHERESIS - Replacement of patients plasma with sterile albumin solution 
cause removal of immunostimulatory factors and cause dilution of cytokines, free antigen 
and antibodies. 
ZAFIRLUKAST- This leukotriene antagonist has been tried in ENL with outcome 
measures not well defined.[63] 
INFLIXIMAB – This chimeric monoclonal antibody suppresses TNF and has been 
reported in a single case of recurrent ENL.[64] 
TREPTERYGIUMWILFERDIN HOOK – A CHINESE HERB –this has been 
reported to be effective in both Type I and Type II with efficacy of 96.6% and 98% 
respectively.[56] 
 
TREATMENT OF COMPLICATIONS IN REACTIONS 
Iritis / iridocyclitis – requires rest, dilation of pupil with mydriatics like atrophine 
and suppression of inflammation with local steroid eyedrops or ointment. 
Epididymo orchitis – bed rest, NSAID and scrotal suspensory bandage gives 
symptomatic relief and steroids help in relieving the inflammation. 
Arthritis / periostitis – Thalidomide and steroids control it rapidly. Temporary 
immobilization, analgesic and anti-inflammatory drugs may be additionally required. 
Glomerulonephritis and amyloidosis – no drugs can reverse the renal pathology 
secondary to immune complex deposition but early and specific treatment can arrest the 
progression. Bed rest, adequate fluid intake, steroids and continuation of anti-leprosy 
drugs are all helpful. 
LEPRA REACTIONS AND HIV [65, 66] 
The relationship between leprosy and HIV infection is not yet fully understood. 
Earlier literature is replete with reports of increase frequency of Type I reaction, severe 
neuritis, poor therapeutic outcome and relapse among HIV infected leprosy patients.[67] 
HIV infected patients responding to HAART developed reaction especially type I 
[RR] as a form of immune reconstitution inflammatory syndrome [IRIS] with a 
possibility of atypical presentation. It is usually seen in first 6months of starting HAART 
and it result from an increase in CMI. In earlier literature HIV infection was thought to 
decrease the risk of ENL. But recent studies Nanda Lal Sharma et al and Geber et al 
recorded a definite higher risk of ENL reaction. [66, 67]  Like other intercurrent infection 
HIV acted as a trigger for ENL reaction and appears to produce severe, recurrent necrotic 
lesions associated with neuritis. HIV is neurotrophic and may cause necrotizing vasculitis 
of the nerve.[68] The interaction of neurotropicity of M. leprae and HIV may result in 
neuropathy that is severe and unresponsive to steroid therapy. Similarly HIV induced 
vasculopathy may aggravate immune complex mediated vasculitis / panniculitis of ENL 
that responds poorly to steroid therapy.[69] 
In case of ENL with HIV, thalidomide [100 – 400mg / day] is the currently 
recommended drug in moderate to severe reaction. Recently it has also been reported to 
produce antiretroviral effect possibly through inhibition of TNF production and by 
blocking TNF stimulated HIV replication.[66] 
PREGNANCY AND LEPRA REACTION [6] 
In pregnancy, there is increased incidence of lepra reactions.  
Type 1 reaction – During pregnancy, downgrading reaction may occur in borderline 
leprosy especially in 3rd trimester due to decrease in CMI. During puerperium, reversal 
reaction is most likely to occur when there is a rapid regaining of CMI. 
Type 2 reaction – In LL, Type 2 reaction is most likely to occur in the 3rd trimester and 
the  puerperium. In the puerperium, reaction is associated with physical stress of 
parturition and reversal of increased plasma ACTH and cortisol to normal level. 
 
 
 
 
 
 
 
 
 
 
 
 
                             MATERIALS AND METHODS 
This study on lepra reaction was conducted among the patients attending skin 
outpatient department, in Department of Dermatology, Govt Rajaji hospital, Madurai 
medical college, Madurai, during the period from Oct 2009 to Sep 2011. Permission from 
ethical committee of the hospital was obtained for this study. The patients were recruited 
for study with fulfillment of following criteria.  
Inclusion criteria 
1. Patients with clinical features suggestive of lepra reaction of any age and sex 
including both, leprosy patients presenting with lepra reaction for the first time 
and already diagnosed cases of lepra reaction presenting with recurrent episodes. 
Exclusion criteria  
1. Patients not willing for the study. 
2. Treated cases of lepra reaction presenting with no active lesions at the time of 
examination. 
 
 
 
 
METHODOLOGY 
HISTORY 
 A detailed history was taken which includes exacerbation of existing skin lesions, 
appearance of new skin lesions with duration, constitutional symptoms, systemic 
complaints, recurrence , neural pain , sudden onset of sensory loss or motor  paralysis, 
onset of symptoms in relation to initiation of antileprosy drugs, and precipitating factors 
if any. 
CLINICAL EXAMINATION 
A detailed general examination and systemic examination was done. Detailed 
dermatological examination was done which included number, morphology, distribution, 
symmetry, tenderness and sensation of skin lesions. Nerve involvement with thickening 
and tenderness, sudden sensory impairment and motor paralysis were noted. The clinical 
type of leprosy was assessed. 
INVESTIGATION 
Routine lab investigation like urine routine, complete blood count, LFT, RFT were 
done. Diagnosis of type of leprosy was confirmed by SSS. Skin biopsy for histopathology 
study done for all patient. 
 
DIAGNOSIS 
Type 1 reaction was diagnosed by erythema and edema of existing skin lesions or 
appearance of new similar lesions with or without nerve tenderness or sudden 
impairement of sensory or motor function. Type 2 reaction was diagnosed by appearance 
of crops of erythematous tender nodules with any one of the following, fever, arthritis, 
neuritis, edema of hands and feet, dactylitis, iritis, epistaxis, epididymo orchitis, 
lymphadenitis. Neuritis was diagnosed by neural pain, nerve thickening and nerve 
tenderness. Both Type 1 and Type 2 reaction were graded according to their severity. 
TREATMENT AND FOLLOW UP 
             MDT started for the new cases according to the type of leprosy and continued for 
those who already on MDT. Both Type 1 and Type 2 reactions were treated with standard 
WHO regimen of 12 weeks of steroid therapy. Tablet Predinisolone 40 mg was started 
with tapering once in 2 weeks. Analgesics were added to neuritic patients along with 
prolonged course of steroid. Antibiotics were added to patients with intercurrent 
infections. 
Clofazimine 300mg was given to patients who had exacerbation and recurrence on 
and off and those who could not be weaned from steroids. Thalidomide was given to 
patient who was recalcitrant to both steroids and clofazimine. All patients were followed 
up for a minimum period of 6months to a maximum period of 12 months. 
TYPE 1 REACTION IN BORDERLINE SPECTRUM  
 
 
  
BT Hansen in Type 1 
 
 
 
           BB Hansen in Type 1 
 
 
 
 
  
BL Hansen in Type 1 
 
 
 
  
Facial patch [BT] in Type 1 
 
TYPE 2 REACTION IN LEPROMATOUS SPECTRUM  
 
 
  
LL Hansen in Type 2 
 
 
 
 
 
 
 
LL Hansen with ENL lesions 
 
 
  
 
BL Hansen with resolving           
ENL lesions 
 
 
 
 
 
Histoid papules and ENL lesions     
in Histoid Hansen 
   
MOTOR DEFORMITIES IN TYPE 1 REACTION  
          
      Left facial palsy in BT Hansen         Left foot drop  in BT Hansen 
 
                                    Left claw hand  in BT Hansen 
 
               CUTANEOUS LESIONS IN TYPE 2  REACTION  
 
 
 
  
Ulcerative ENL in LL  
 
 
 
 
Pustular ENL in LL  
 
 
  
 
 
Necrotic ENL in LL   
 
 
 
 
 
 
 
ENL plaque and nodule in LL 
 
 
 
EXTRA CUTANEOUS FEATURES IN TYPE 2 REACTION  
 
 
  
Bilateral iritis in LL 
 
 
 
 
Dactylitis in LL   
 
 
 
 
Inguinal lymphadenitis in LL  
 
 
 
  
Edema of hands & feet in LL   
 
 
 
HISTOPATHOLOGY OF TYPE  1  REACTION 
[Biopsy from reactional patch in BT Hansen with Type 1 reaction] 
 
Epitheloid granuloma with giant cells  
dispersed by dermal edema    
 
 
Periappendageal epitheloid granuloma with giant cells 
dispersed by dermal edema 
HISTOPATHOLOGY OF TYPE 2 REACTION 
[Biopsy of ENL nodule in LL Hansen with Type 2 reaction] 
 
 
Septal panniculitis with neutrophilic vasculitis  
 
 
Septal panniculitis with neutrophilic infiltrate    
AFB BACILLI IN SPLIT SKIN SMEAR 
 
Clumps of AFB bacilli admixed with neutrophils (from ENL pustule)      
 
Fragmented AFB Bacilli ( from ENL nodule )  
 
  
 
 
 
 
 
 
                 OBSERVATION AND RESULTS 
Total no of cases attended the skin department (both inpatient and outpatient) in 
this 2 year study was 1,03,536. Out of which 63 patients were diagnosed to be having 
lepra reaction and were included in the study based on inclusion criteria. The overall 
incidence of lepra reaction was found to be 0.06%. Out of 63patients, 38 were Type I and 
25 were Type II reaction. No case of type III reaction was reported 
Table 1 : Age distribution 
Age group 
Type 1 Reaction Type 2 Reaction 
No % No % 
< 20 years 2 5.2 - - 
21- 30 Years 13 34.2 6 24 
31- 40 years 9 23.7 5 20 
41-50 years 7 18.4 4 16 
> 50 years 7 18.4 10 40 
Total 38 100 25 100 
Range 15-63 years 22-61 years 
Mean 37.8 years 43.8 years 
 
 
  
 
 
 
 
 The Type 1 reaction cases had an mean age of 37.8 years and the Type 2 reaction 
cases had an  mean age of 43.8 years.  In our study,  Type 1 reaction was common in 21 - 
30yrs of age group [34.2%]  and Type 2  was commonly seen above 50yrs of age [40%]. 
The youngest patient in the study group was 15 years of age and the oldest studied was 
68 years of age. Both of them were male patients. 
                                                   Table 2 : Sex distribution 
 
 
 
 
 
          
 
              There were total of 47 males and 16 females presented with lepra reaction with 
the sex ratio of 2.9 : 1. The sex ratio of Type 1 and Type 2 reaction were 3.8 : 1 and      
2.1 : 1 respectively. 
 
                         
Sex 
Type 1 Reaction Type 2 Reaction 
No % No % 
Male 30 78.9 17 68 
Female 8 21.1 8 32 
Total 38 100 25 100 
REACTIONS IN VARIOUS SPECTRUM OFLEPROSY 
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Table 3: Type of reaction in various spectrum of leprosy 
 
 
 
 
 
 
 
 
 
 
 
 
 
              BT type of leprosy was predominant (81.5%) in Type 1 reaction cases and LL in 
Type 2 reaction cases (72%). Among 38 patients of Type 1 reactions, 31 [81.5%] cases 
were BT, 4 [10.5%] cases were BB and 3 [7.9%] cases were BL. Among Type 1 reaction 
all cases were upgrading except for one case which downgraded from BT to BL. Out of 
25 cases of Type 2 reaction, 4 [16%] cases of BL, 18 [72%] cases of LL and 3 [12%] 
cases of Histoid Hansen were reported. 
                      
 
Type of leprosy 
Type 1 Reaction Type 2 Reaction 
No % No % 
BT 31 81.5 - - 
BB 4 10.5 - - 
BL 3 7.9 4 16 
LL - - 18 72 
            Histoid - - 3 12 
Total 38 100 25 100 
               Table 4: Occurence of reaction in relation to Anti Leprosy drugs 
 
Anti-Leprosy 
drugs 
Type 1 Reaction Type 2 Reaction 
No % No % 
 
Drugs taken 
Drugs not taken     
[ de novo] 
20 
18 
52.6 
47.4 
18 
7 
72 
28 
Total 38             100          25          100 
 
Out of 38 cases of Type 1 reaction, 18 cases occurred de novo without any relation 
to the anti-leprosy drug, 20cases [52.6%] developed reactions after the intake of 
antileprosy drugs. Out of 25 cases of Type 2 reaction, 7cases [28%] developed reaction 
de novo, 18 cases developed after intake of drugs.  
 
         
 
 
       Table 5: Onset of reaction in relation to the initiation of antileprosy drugs 
Duration from the 
initiation of drug 
 
         Type 1  Reaction Type 2 Reaction 
No % No % 
< 3 months 5 25 2 11.1 
4-6 months 1 5 2 11.1 
7-12 months 5 25 4 22.2 
1-2 years 3 15 6 33.3 
3-5 years 3 15 1 5.6 
> 5 years 3 15 3 16.7 
 
It was observed that 25% of Type 1 reaction developed within 3months of taking 
the drug and another 25% developed Type 1 reaction after 7 – 12 months of taking the 
drug. In Type 2 reaction 33% of cases and 22% of cases developed the reaction after 1-2 
years and 7- 12 months of taking the drugs respectively. Five cases of reaction [2- Type 1 
and 3- Type 2] had dapsone monotherapy form of anti-leprosy treatment and all others 
had MDT regimen. 
                  
                  
                 
               Table 6 : Total cases presented with  precipitating [ppt] factors 
      
Among 38 cases of Type 1 reaction, 30 patients had precipitating factors. Single 
precipitating factors was present in 23 cases [60.5%] and multiple ppt factors was seen in 
7 cases [18.4%]of Type 1. Without any precipitation, 8 cases [21%] developed Type 1 
reaction. Precipitating factors in form of single and multiple factors were present in all 
patients of Type 2 reaction. 
 
 
 
 
                                         
                                      
Precipitating factors  Type 1 reaction Type 2 reaction 
Single  ppt. factor 23 60.5 18     72 
Multiple ppt. factors 7 18.4 7 28 
Nil factors 8 21 - - 
Total 38 100 25 100 
                                   Table 7 :  Various precipitating factors  
 
Precipitating factors 
Type 1 Reaction Type 2 Reaction 
No % No % 
Antileprosy drugs 20 52.6 18 72 
Physical stress 9 26.5 4 16 
Mental stress - - 2 8 
Inter current infection 3 8.8 3 12 
Surgery 2 5.9 3 12 
Postpartum  - - 1 4 
Trauma 2 5.9 1 4 
 
The main precipitating factor in the study was intake of antileprosy drugs which 
was present in 20 patients of Type 1 and 18 patients of Type 2 reaction. Among the 
precipitating factors other than ALD, physical stress constituted 26.5% and intercurrent 
infection [viral hepatitis, typhoid, chicken pox] constituted 8.8% in Type 1 reaction. In 
Type 2 reaction 4 cases were precipitated by physical stress, 3 cases were precipitated by 
surgery [cataract surgery, hernioraphy, orthopedic surgery] and inter current infection 
each. 
                                               
                                         Table 8 : Constitutional symptoms 
Constitutional 
symptoms 
  Type 1 Reaction Type 2 Reaction 
No % No % 
Present 14 36.8 24 96 
Absent 24 63.1    1 4 
Total  38 100     25 100 
 
Constitutional symptoms were present in only 36.8% of Type 1 cases. But 96% of 
Type 2 cases had them. The constitutional symptoms taken into account both in Type 1 
and Type 2 were fever, arthralgia and malaise. 
 
 
 
 
 
                                                    
                                                     Table 9 : Cutaneous features 
  
 Cutaneous features 
 Type 1 Reaction Type 2 Reaction 
No % No % 
Erythema  & edema of old lesion 29 79.3 - - 
New similar lesion 6 15.8 - - 
Nodule - - 25 100 
Plaque [subcutaneous ] - - 8 32 
Pustule - - 1 4 
Ulcer - - 5 20 
 
Erythema and edema of old lesions were present in 79.3% of Type 1 cases and 
15.8% showed new similar lesion. Nodules were present in 100 % of Type 2 cases. Ulcer 
was seen in 5cases of Type 2. One case of pustular ENL was observed. 
 
                        
                                   
                          Table 10: Extracutaneous features 
Extracutaneous 
features 
 Type 1 Reaction  Type 2 Reaction 
No % No % 
Edema of hands 10 26.3 11 44 
Edema of feet 5 13.2 13 52 
Dactylitis 2 5.3 5 20 
Iritis - - 1 4 
Epistaxis - - 2 8 
Epididymo orchitis - - 3 12 
Lymphadenitis - - 4 16 
 
Edema of hands and feet were noted in both Type 1 and Type 2 reaction. In Type 
2 reaction, 11 cases [44%] and 13cases [52%] manifested with edema of hands and feet 
respectively. Dactylitis was present in 2 cases and 5 cases of Type 1 and Type 2 reaction. 
Among 25 cases of Type 2 reaction, 1 case of Iritis, 2 cases of epistaxis, 3 cases of 
Epididymo-orchitis and 4 cases of Lymphadenitis were observed. 
 
                                          NEURITIS IN REACTIONS 
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                                                             Table 11 : Neuritis 
Neuritis 
Type 1 Reaction Type 2 Reaction 
No % No % 
Single nerve 22 57.9 4 16 
Multiple nerves 12 31.5 9 36 
No neuritis 4 10.5 12 48 
Total  38 100 25 100 
 
Neuritis was seen in most cases [89.4%] of Type I reaction as single neuritis in 
57.9% and multiple neuritis in 31.5% whereas neuritis was seen only in 52% of Type 2 
cases. Ulnar nerve and lateral popliteal nerve were the common nerves involved in 
neuritis. 
 
 
 
 
 
Table 12 :  Sensory impairment along the course of neuritis 
Sensory           
impairment 
Type 1 Reaction Type 2 Reaction 
No % No % 
Present 21 55.3 8 32 
Absent 13 34.2 5 20 
 
          Sudden onset of sensory impairment in form of altered sensation, pain, extend of 
anesthesia in areas supplied by the affected nerve was present in 55.3% of Type 1 cases 
and 32% of Type 2 cases. 
 
 
 
 
 
 
 
 
                 MOTOR PARALYSIS IN REACTIONS 
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                                                    Table 13 : Motor paralysis 
Motor palsy 
Type 1 Reaction Type 2 Reaction 
No % No % 
Claw hand 3 7.9 1 4 
Foot drop 6 15.8 - - 
Facial palsy 3 7.9 - - 
Nil 26 68.7 24 96 
Total 38 100 25 100 
 
 Out of 38 cases of Type 1 reaction, 3cases developed claw hand, 6 cases 
developed foot drop and 3 cases developed facial palsy. There was only one motor palsy 
[claw hand] noticed in Type 2 reaction. 
 
 
 
 
 
Table 14: Skin biopsy 
Histopathological 
features 
Type 1 Reaction Type 2 Reaction 
No % No % 
Dermal edema 26 68.4 - - 
Epitheloid granuloma 28 73.6 - - 
Dermal infiltration 
superimposed on foamy 
macrophages 
2 5.2 22 88 
Panniculitis - - 21 84 
Neutrophilic vasculitis - - 14 56 
 
Dermal edema and epitheloid granuloma dispersed by dermal edema were 
observed in 26 cases and 28 cases of Type 1 respectively. Lymphocytes infiltrate 
admixed with macrophage were observed in 2 cases of Type 1 in BL spectrum. 
Neutrophilic infiltrate super imposed on foamy macrophage granuloma noticed in 22 
cases of Type 2 reaction. Panniculitis and neutrophilic vasculitis were seen in 21cases 
and 14 cases of Type 2 reaction respectively. 
 
  
RESPONSE TO STEROID REGIMEN 
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                                   Table 15: Response to WHO Steroid regimen 
 
Response Type 1 reaction Type 2 reaction 
No % No % 
Good 34 89.5 17 68 
Exacerbation < 12 weeks 3 7.9 2 8 
Exacerbation > 12 weeks 1 2.6 3 12 
Recurrence & Recalcitrant - - 3 12 
Total 38 100 25 100 
 
  Response to WHO steroid regimen was good in 89.5% of Type 1 reaction cases 
and 68% of Type 2 reactions.  Exacerbation was noticed before 12 weeks in 3cases of 
Type 1 and 2 cases of Type 2 reaction. Exacerbation after 12 weeks was noticed in one 
case of type 1 and 3 cases of Type 2 reaction. Three cases of Type 2 reactions showed 
recurrent episodes and dependent on steroids. Even after addition of clofazimine, 
recurrence occurred in that 3 cases and became recalcitrant. Out of 3 one case responded 
well to thalidomide.  
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Table 16: Bacteriological Index [BI] 
Bacteriological 
Index 
Type 1 reaction Type 2 reaction 
No % No % 
Negative 34 89.5 - - 
1 +  to  3 + 4 10.5 6 24 
4+  to  5+ - - 15 60 
> 6+ - - 4 16 
Total 38 100 25 100 
 
Bacteriological index was negative in 89.5% of Type 1 reaction cases and 4 cases 
showed BI of 1+ to 3+ in Type 1 reaction. In Type 2 reaction 60% showed 
bacteriological  index of  4+ to 5+,  24% showed BI of 1+ to 3+ and 16% showed BI of  
> 6+.  
 
 
 
                           
                              DISCUSSION 
INCIDENCE 
Out of 1, 03,536 patients attending the skin department, 63 patients were found to 
have lepra reaction. Out of which Type 1 reactions constituted 0.04% and Type 2 reaction 
constituted 0.02%. The overall incidence of lepra reaction observed in our study was 
0.06%. 
AGE 
           In our study, 34.2% of Type 1 reaction belonged to the age group of 21 -30 years 
followed by 23% in 31 – 40years. This age incidence is comparable with the study 
conducted by Scollard et al in which the highest age incidence for Type 1 reaction 
mentioned was 21 – 40 years.[70]  In our study no patient of < 20 years was presented with 
Type 2 reaction. All were above 20 years of age. This is comparable with Scollard et al 
study in which 83% of Type 2 reaction belonged to the age group of 20 years and above. 
Mnandhar et al in his study observed patients older than 40years were at significantly 
decreased risk of ENL.[71] But in our study majority of ENL cases [56%] were above 40 
years of age.  
SEX  
         In our study lepra reactions both Type 1 and Type 2 were found in an incidence of 
74 % among males and 25% among females. The incidence of male predominance is 
comparable with the studies done at Belgian leprosy centre, Polambakkam, 
Madurantakam, South India and Job et al.[35,72] The female incidence clearly correlates 
with the 26% of female incidence observed in the Scollard et al study.[70] 
INCIDENCE IN VARIOUS SPECTRUM OF LEPROSY 
In our study, among the 38 patients who had Type 1 reaction, 31 patients were BT, 
4 were BB and 3 were BL. Thus BT patients had higher incidence of Type 1 reaction. 
Out of 25 patients who had Type 2 reactions, 4 were of BL and 18 were of LL and 3 were 
of Histoid Hansen. 
In the study of Desikan et al, out of 412 patients who presented with Type I 
reaction 313 patients had BT, 9 patients had BB, 85 patients had BL and 5 patients had 
LL. Among 95 patients who had Type II reaction 61 had LL and 34 had BL. [73] 
In the study of Seghal et al, out of 22 patients who presented with reaction 11 were 
of Type I (BT-6, BB-1, BL-4) and 11 patients were of Type II reaction and all the 
patients belong to LL spectrum in Type 2. [74] 
In Histoid leprosy, ENL reaction has been reported by some authors, Bhutani 
found ENL reaction in 3 of 20 Histoid patients.[75] Kaur et al observed ENL in 40% of 
Histoid patients. [39] 
Thus the type of reaction and its relation to the clinical leprosy in our study is 
almost similar to the observations made in the above studies 
ONSET OF REACTION IN RELATION TO ANTILEPROSY DRUGS 
In our study, among 38 cases of Type 1 reaction, 18 patients [47.4%] developed 
reaction before initiation of MDT [de novo] and among 25 cases of Type 2 reaction, 7 
patients [28%] developed it before initiation of MDT. This is comparable with the Kumar 
et al study in which he observed the time of onset of reaction as follows, 35.9 % 
presented with type 1 reaction at the time of first visit to the leprosy clinic and 19.75% 
presented with Type 2 reactions at the time of first visit. [14] 
In our study, the patients after starting MDT, developed Type 1 reaction mostly 
[25%] during 6 -12 months of starting drugs and 33% of Type 2 reactions developed 
during 1 -2 years of starting MDT. This is well comparable with Kumar et al study who 
reported that the incidence of Type 1 was highest during 6 -12 months after starting MDT 
and also reported that ENL occurred mostly during 2nd or 3rd year following MDT.[14]  
PRECIPITATING FACTORS 
In our study, antileprosy drugs [60.3%] constituted the major risk factor for 
precipitating lepra reactions.  Other factors like physical stress [20.6%], intercurrent 
infections [9.5%], surgery [7.9%] all constituted some risk in precipitating both type 1 
and Type 2 reactions.  The precipitating factors in our study correlate with those of 
Kumar et al. [14] 
 
CLINICAL FEATURES OF TYPE 1 REACTION 
The predominant clinical features of Type 1 reaction observed in our study were 
raised erythematous skin lesion [79.3%], neuritis [89.4%] and constitutional symptoms 
[36.8%]. Hastings mentioned that the erythema and swelling of the existing lesion and 
neuritis, the predominant features in cases of Type I reaction along with mild 
constitutional feature like fever. This has been mentioned by Jopling also. So the 
predominant features in our study are concurrent with those of Hastings’ and Jopling’s.  
In the study of Lockwood et al, 31.8% had only neuritis and 22.7% had both skin 
lesions and neuritis. [76]  In comparison with Lockwood study the incidence of neuritis 
was very much higher in our study. Single neuritis was commonly seen than multiple 
neuritis. Deformities like claw hand, foot drop and facial palsy were seen in 7.9%, 15.8% 
and 7.9% respectively. In our study, foot drop was seen in higher incidence in contrast to 
Richardus et al study who mentioned that the most commonly involved nerves of motor 
function deformity during reactions were the ulnar.[77] Both Richardus and Sharma 
reported that 7.9% of patients developed claw hand due to Type 1 reaction.[77, 78] This is 
concurrent with the incidence of claw hand in our study. Other features observed in our 
study were edema of hands, edema of feet and dactylitis seen in 26%, 13% and 5.3% 
respectively. 
 
 
CLINICAL FEATURES OF TYPE 2 REACTIONS 
In the present study, 100% of Type 2 reaction patients presented with crops of 
erythematous and tender nodules, subcutaneous plaque along with nodule was seen in 
32% of patients. Ulcerative lesion was seen in 5cases and pustular lesion in one case. 
Constitutional symptoms [96%] (like fever, arthralgia and malaise), neuritis [52%], 
edema of feet [52%], edema of hands [44%] were the next common clinical features. 
Dactylitis [20%], lymphadenitis [16%], epididymo-orchitis [12%] epistaxis [8%] and 
iritis [4%] were the least features encountered. 
Van Brakel et al study shows presence of following clinical signs is diagnostic of 
ENL i.e., multiple, tender nodules, with or without ulceration, neuritis (shooting or 
burning), fever, edema, involvement of other organs, e.g., Iritis, orchitis and arthritis.[79] 
The features are almost in concurrence with the present study.   
HISTOPATHOLOGY 
Biopsy taken from the erythematous tender plaque of Type 1 reaction cases 
showed epitheloid granuloma in almost all cases. But the characteristic features of Type 1 
reaction such as edema in the dermis with hazy collagen fibers and epitheloid granuloma 
dispersed by dermal edema was seen in 68.4% and 73.6% respectively. Other features 
like increased lymphocytes, multi nucleated giant cells, foci of fibrinoid necrosis and 
destruction of the appendages were also observed. All this features are comparable with 
similar features mentioned in Ridley DS and Radia KB.[80] In 2 cases of Type 1 reaction 
belonging to BL spectrum and downgrading type, lymphocytes admixed with 
macrophages were observed which is also concurrent with the findings of Ridley and 
Radia. 
In Type 2 reaction of 25 cases, 88% patients had neutrophilic infiltration of the 
dermis overlying foci of foamy macrophages, and 84% showed panniculitis.  Vinod 
Kumar Sharma in his study mentioned that polymorphonuclear invasion of the vessel 
wall is a characteristic finding in ENL. [81]  In 56% of cases neutrophilic vasculitis was 
observed and this proved the characteristic finding of ENL in comparison with Vinod 
Kumar Sharma study. 
RESPONSE TO STEROIDS 
 During the follow up of minimum 6 months to maximum 1year period, 34 
patients [89%] of Type 1 reaction showed good response. Exacerbation was seen in 4 
cases [10.5%] with 7.9% developed it < 12 weeks and 2.6 % developed it > 12 weeks. All 
that 4 cases treated with prolonged steroids. Rao et al in his study suggested longer 
duration of prednisolone treatment gave less poor outcomes than a short course of 
prednisolone.[82] Good response to short course regimen is thus correlated with the 
findings of Rao. 
Out of 25 cases of Type 2 reaction, 68% responded well to steroid, 8 patients 
[32%] went for exacerbation in form of recurrent episodes. They were treated with 
prolonged steroids and few were added with high dose clofazimine. Out of that 8patients, 
3cases [12%] developed multiple reccurences and became recalcitrant. This finding is 
correlated with the study of Shen et al who found that the standard 12 week regimen of 
prednisolone was effective only for mild Type 1 and Type 2 reaction cases but was not 
effective for severe cases of reactions especially Type 2 reactions.[83] 
 
BACTERIOLOGICAL INDEX [BI] IN REACTIONS 
 
BI was negative in 34 cases [89.5%] and positive in 4 cases [10.5%] of Type 1 
reactions. All the positive cases showed BI < 3+. All cases of Type 2 reaction were 
positive for BI. Out of 25 cases, 6 cases [24%] showed BI < 3+, 15 cases [60%] showed 
BI  4+ to 5+ and  4 cases [16%] showed  BI  > 6+. This is very much comparable with 
Nery et al study who mentioned that the RR rate was significantly higher among patients 
showing BI < 3, while ENL predominated among those patients with BI > 3.[84] 
Manandhar et al mentioned that there was a linear relationship in the risk of ENL with an 
increasing BI [bacterial index (BI) of > 4+].[71] Our study confirmed this finding by 
showing 76% of BI > 4+ in Type 2 reaction. 
 
 
 
 
 
 
 
                                                SUMMARY 
 63 patients with clinical features of lepra reaction were included in the study. 
 38 cases of Type 1, 25 cases of Type 2, no case of Type 3 reaction were observed. 
 Overall incidence of lepra reaction was 0.06%. 
 Mean age for Type 1 was 37.8yrs and mean age for Type 2 was 43.8yrs. 
 Male preponderance was observed with sex ratio of 2.9:1. 
 More number of BT patients had Type-I reaction and more number of LL patients 
had type II reaction. 
 Anti-leprosy drugs were found to be the most common precipitating factor 
followed by physical stress and intercurrent infection. 
 Erythema and swelling of the skin lesions, neuritis and edema of hands and feet 
were common features of Type I reaction.  
 Neuritis was most commonly seen in Type 1 than inType 2 reaction. 
 Sensory and motor deformities were seen in 46% and 20.6% of cases. 
 Crops of tender evanescent nodules, fever, joint pain, neuritis and edema of hands 
and feet were common in Type 2 reaction. 
 Pustular and ulcerative type of ENL lesions were present in signicant number.  
 Classical histopathological features were present in three fourth of cases. 
 Steroids are effective in 89% of Type 1 and 68% of Type 2 reaction. 
 BI was <3+ in Type 1 and >4+ in Type 2 reaction. 
 
CONCLUSION 
TYPE 1 REACTION  
Type 1 reaction was the most common type of reaction seen. The majority of the 
patients with Type 1 had BT hansen. Most of the patients developed it after 6-12 months 
of starting MDT and significant proportion of cases developed de novo. Antileprosy 
drugs were found to be the commonest precipitating factor followed by physical stress 
and intercurrent infection. Neuritis was the predominant clinical feature observed 
followed by erythema/swelling of the skin lesion and edema of  
hands /feet. Motor paralysis in form of foot drop, claw hand and facial palsy were 
significantly observed. Dermal edema with dispersed epitheloid granuloma were the 
predominant histopathological features observed. Exacerbation of Type 1 reaction was 
commonly observed during tapering of steroids [< 12 weeks]. Interesting observation of 
shift from BT to BL was observed in one case. 
TYPE 2 REACTION 
Type 2 reaction was observed predominantly in LL and rarely in BL. Most of the 
patients developed it after 1-2 years of antileprosy drugs. Seven cases presented with 
ENL at their first visit [de novo]. Erythematous tender nodules, fever, edema of hands / 
feet and neuritis were the predominant clinical features. Rare variants of pustular and 
ulcerative ENL were also observed. Iritis and epididymo-orchitis were seen in few cases. 
Neutrophilic infiltration of dermis with panniculitis and vasculitis were the predominant 
histopathological features observed. Exacerbation and recurrence of Type 2 reaction were 
commonly observed after withdrawal of steroids [> 12 weeks], which insists the need for 
prolongation of steroids. There was a linear relationship in the risk of ENL with an 
increasing BI. An interesting observation in our study was, 3 patients primarily diagnosed 
as Histoid Hansen developed Type 2 reaction, which has also been observed in some 
recent studies.  
Early diagnosis, adequate treatment and proper follow up are very essential to 
prevent the deformities and systemic complications associated with lepra reactions. 
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                                        PROFORMA 
 
NAME:  
 
AGE / SEX: 
 
ADDRESS: 
 
OCCUPATION / INCOME: 
 
SOCIOECONOMIC STATUS: 
 
HANSEN IN FAMILY MEMBERS: 
 
DATE OF DETECTION : 
 
DURATION OF DISEASE: 
 
DATE OF REPORTED : 
 
TYPE OF HANSEN :   TT   /BT  /BB  /BL  /LL  /Neural /Histoid  
 
NATURE OF TREATMENT :  PB MDT  /MB MDT 
 
DATE OF Rx STARTED : 
 
DURATION OF TREATMENT: 
 
RELEIVED FROM TREATMENT: 
 
CHIEF COMPLAINTS ; [ with duration ] 
 
         Skin lesion : 
 
         Systemic complaints: 
 
 
 
 
 
 
HOPI 
 
       Onset – sudden / insidious 
 
       Progression – slow / rapid 
 
       Skin lesion – old lesion 
 
                          - new lesion 
 
     Site - 
 
     Distribution - 
 
     Sensation – Loss of sensation / painful 
 
     No/ of recurrences 
 
     Duration between recurrences 
 
     Rx at recurrences 
 
Constitutional symptoms –  Fever / arthralgia / malaise / fatigue / headache 
 
Neuritis – Neural pain / tingling and numbness 
 
                Extent of anaesthesia 
 
                Sudden motor palsy / weakness 
 
Systemic involvement –  
 
                Eye – redness / blurring of vision / pain / photophobia 
 
               Edema of hands & feet 
 
               Swollen & tender testis 
 
               Muscle pain & bone pain 
 
               Joint pain & swelling 
 
               Rhinitis / epistaxis / acute resp. obstruction 
PAST H/O 
  
       DM / HT / other  systemic disease 
 
      Hansen in the past – yes / no 
 
      If yes – when  
 
                 - Type of Hansen 
                   
                 [ from record /  no/- of patch /    no/- of nerve ] 
 
     Any ppt factors –  [ surgery / vaccination / IC infection / pregnancy / drugs / lactation /  
 
                                     menstruation / Physical stress / mental stress / trauma / others] 
 
TREATMENT H/O 
 
          ALT taken in the past – 
 
          Regimen taken               Dapsone monotherapy /  ROM  
 
                                                 PB MDT                      /                  MB MDT 
 
        Date of Rx Started on - 
 
        Date of  completion  - 
 
        RFT - 
 
        Default / regular / dropout - 
 
PERSONAL H/O 
 
       Single / married                                                                  Smoking 
 
      Children                                                                               Alcohol 
 
      Family Planning                                                                  Betelnut chewer 
 
 
 
 
GENERAL EXAMINATION 
 
            Febrile  
 
           Anemic 
 
           Jaundice 
 
           Pedal edema 
 
           Gen LN 
    
           Reg LN 
 
VITALS – P.R / B.P 
 
SYSTEMS – CVS / RS / ABD / CNS  
 
DERMATOLOGICAL EXAMINATION 
 
New lesion  ;  Type – Nodule 
 
                                   Plaque 
 
                                   Vesicle / bulla 
 
                                   Ulcer / necrosis 
 
Old lesion; Type – Patch 
 
                               Plaque 
 
Margin – Well / ill defined 
 
                Extent of margin 
 
Surface – Warm  
 
                Shiny / edematous 
 
                Scaly / exfoliation 
                
                Dry & wrinkled / scar 
Color – Erythematous / Skin color 
 
             Hypopigmented / Hyperpigmented 
 
 
Infiltration 
 
Tenderness 
 
Site 
 
Distribution – Symmetrical / Asymmetrical  / U/L    /     B/L  
 
Sensation – Hypoaesthetic / Hyperaesthetic / Anesthetic  
 
Other skin lesion – Madrosis 
 
                               Nasal depression 
 
                               Ear lobe infiltration 
 
                               Leonine facies 
 
                               Edema /exfoliation in hands & feet 
 
                              Gyanecomastia 
 
NERVE EXAMINATION 
 
      CRANIAL NERVE;  5th nerve  - Corneal sensation 
 
                                                           - Sensation on face 
 
                                        7th nerve  –  Facial expression 
 
                                                          - Wrinkling of forehead 
 
                                                          - Blinking of eye 
 
                                                          - Deviation of mouth 
 
                                                          - Lid lag 
 
PERIPHERAL NERVES               RIGHT                LEFT               firm/soft/tender 
 
Supraorbital nerve  
 
Infraorbital nerve 
 
Facial nerve 
 
Greater auricular nerve 
 
Supraclavicular nerve 
 
Radial nerve 
 
Ulnar nerve 
 
Median nerve 
 
Radial cutaneous nerve 
 
Ulnar cutaneous nerve 
 
Lat popliteal nerve 
 
Post tibial nerve 
 
Sural nerve 
 
Sup peroneal nerve    
 
Any feeding nerve  - thickened / tender 
 
 
SENSORY SYSTEM 
 
   Anaesthesia along nerve course  -  partial / complete loss 
 
   Extent of anaesthesia / Distribution of sensory impairment 
 
   Glove & stocking anaesthesia 
 
 
 
MOTOR SYSTEM 
 
     Acute palsy – Claw hand  -  partial / total  
 
                            Wrist drop 
 
                            Foot drop 
 
                            Facial palsy 
 
    VMT – Ulnar nerve  - Little finger abduction   
 
                                        Card test 
 
                                        Froment’s sign 
                 
                Radial nerve – wrist extension 
 
                Median nerve – pen test 
 
                Lateral popliteal nerve – dorsiflexion of foot 
 
                Posterior tibial nerve – eversion of foot 
 
OTHER SYSTEMS 
 
          Eye – iritis / Conjunctivitis / iridocyclitis / scleritis 
 
          Dactylitis -  Edema / Tenderness 
 
          Lymphadenitis – firm / Tender 
  
                                      Site –  
 
         Epididymo orchitis – swelling / Tenderness 
 
         Myositis – muscle tenderness 
 
         Arthritis – jt swelling / tenderness 
 
         
 
 
INVESTIGATION 
 
       Urine - Alb - [proteinuria] 
 
                    RBC – [hematuria] 
          
       Blood – TC  
 
                     DC 
                     
                     ESR 
 
                     Hb /- 
 
                    Other findings 
     
     RFT –  
 
     LFT 
     
    USG ABD - renal 
 
    SSS – BI  /  MI 
 
    BIOPSY -  Site 
 
                       Report with biopsy no/ 
 
 FINAL DIAGNOSIS; 
 
REACTION GRADING - 
 
TREATMENT; Steroids  started  
 
                                         Tapered 
 
                                         Response 
 
                            Other drugs- 
 
FOLLOW UP: Date                              Clinical progress                            Rx tapering 
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1 Ramu 50 M 2 4 1 11 PS 1   1 0     0 1 
2 Malaisami 58 M 2 4 1 7  1   1 0 0 0 
3 Mohammed Yusuf 15 M 1 1 1 3  1 1 1     
4 Amose 52 M 2 5 1 18 PS 1   1 0 0 0 
5 Kannammal 50 F 1 1 0   0 1 0     
6 Selvam 50 M 1 1 0   0 1 0     
7 Seethalakshmi 37 F 2 5 1 11  1   1 1 0 0 
8 Vasu  31 M 1 1 1 1 PS 0 0 0     
9 Tharamani 40 F 1 1 1 12  0 1 0     
10 Janaki 30 F 2 4 1 24  1   1 0 0 0 
11 Velusamy 38 M 1 2 1 9  0 1 1     
12 Papathi 21 F 1 1 0  IC 0 1 0     
13 Pattamuthu 54 M 1 2 1 60  0 1 1     
14 Sathish kumar 15 M 1 1 1 2  1 1 0     
15 Raj konar 53 M 2 4 0  PS 1   1 0 0 0 
16 Andichi 30 F 1 1 1 11  1 1 0     
17 Arumugam 63 M 1 1 1 12  0 1 0     
18 Kottaisamy 61 M 2 4 1 120 IC 1   1 0 0 0 
19 Gopi 24 M 2 4 1 2  1   1 0 0 1 
20 Fathima 50 F 1 1 0   0 0 0     
21 Balakrishnan 58 M 1 1 1 6  0 1 0     
22 Nagaraj 21 M 1 1 1 24  0 1 1     
23 Hariharan 33 M 1 2 0  S 0 1 0     
24 Selvi 31 F 2 4 0  L 1   1 1 0 0 
25 Pandiammal 40 F 2 3 0  S 1   1 1 0 0 
26 Bose 53 M 2 5 1 6 IC 1   1 0 0 0 
27 Panju 50 F 1 1 0  PS 1 1 0     
28 Sayeed 57 M 1 2 0   0 1 0     
29 Papu 32 F 1 1 1 120  1 1 0     
30 Selvi 30 F 2 4 1 4  1   1 0 0 0 
 
 
 
 
 
 
 
 
 
 
 
MASTER CHART 
 
      
Onset of reaction 
in relation to ALD  CUTANEOUS 
S.
no
 
N
am
e 
A
ge
 
S
ex
 
Ty
pe
 O
f R
ea
ct
io
n 
Le
pr
os
y.
 T
yp
e 
In
ta
ke
 
  D
ur
at
io
n 
[m
on
th
s]
 
O
th
er
 P
P
T 
 
C
on
st
.S
ym
p.
 
E
ry
th
em
a 
&
 e
de
m
a 
 o
f o
ld
 le
si
on
 
N
ew
 s
im
ila
r l
es
io
n 
N
od
ul
e 
P
la
qu
e 
P
us
tu
le
 
U
lc
er
 
31 Syed Ahmed 40 M 2 4 1 120  1   1 0 0 0 
32 Ebinezar 40 M 1 1 0   0 1 0     
33 Balasubramanian 61 M 1 1 1 10 T 0 1 1     
34 Mookan 43 M 1 3 0  PS 1 1 0     
35 Abdul majid 41 M 2 4 1 24  1   1 1 0 0 
36 Vasanthi 50 F 2 4 1 1  1   1 0 0 1 
37 Shankar 68 M 2 4 1 240  1   1 0 0 0 
38 Balakrishnan 42 M 1 3 1 240  1 1 0     
39 Marimuthu 22 M 1 1 0  IC 1 1 0     
40 Chetty 60 M 1 1 0   0 0 0     
41 Jeyamani 37 M 1 1 0   1 1 0     
42 Karuthammal 50 F 2 3 0  MS 1   1 1 0 0 
43 Parvathi 55 F 2 3 0  MS 1   1 0 1 0 
44 Palanisami 60 M 2 4 0  S 1   1 0 0 1 
45 Sundar 29 M 1 1 1 72 PS 0 1 0     
46 Ponraj 37 M 1 1 0  T 0 0 0     
47 Kumar 30 M 1 1 0  PS 0 0 0     
48 Murugesan 48 M 1 1 1 2 PS 0 1 1     
49 Muthupandi 30 M 1 3 1 2 PS 1 1 0     
50 Velu 27 M 1 1 0  IC 1 1 0     
51 Sivakumar 21 M 1 1 0   1 1 0     
52 Saviriraj 60 M 2 4 0  S 1   1 1 0 1 
53 Ganesan 51 M 2 4 1 36 IC 1   1 0 0 0 
54 Sivaraj 26 M 2 4 1 18 PS 1   1 1 0 0 
55 Stalin 22 M 2 3 1 18  1   1 1 0 0 
56 Chinnasamy 37 M 2 4 1 11 T 1   1 0 0 0 
57 Manimaran 30 M 2 4 1 24  0   1 0 0 0 
58 Moorthi  23 M 1 1 1 24  1 0 0     
59 Kumar  28 M 1 1 0   0 0 0     
60 Muthu 56 M 1 1 0  S 0 1 0     
61 Malliga  39 F 1 1 1 24  1 0 0     
62 Madurai veeran 25 M 1 1 1 36 PS 0 1 0     
63 Chella pandi 30 M 1 1 1 36 PS 0 0 0     
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1 Ramu 1 0 1 0 0 0 0 M P 1     1 1 1 good 6+ 
2 Malaisami 0 0 0 0 0 0 0 M P      1 1  Exa. > 12 wks 2+ 
3 Mohammed Yusuf 0 0      S P    1 1    good - ve
4 Amose 0 0 0 0 0 0 0 0 A      1 1  recurrence 4+ 
5 Kannammal 0 0      S A    1 1    good - ve
6 Selvam 0 0      M P  1      1 1    good - ve
7 Seethalakshmi 0 1 0 0 0 0 0 M P      1 1 1 good 6+ 
8 Vasu  0 0      M A   1      good - ve
9 Thavamani 0 0      S A    1 1    good - ve
10 Janaki 1 0 0 0 0 0 0 0 A      1 1  good 4+ 
11 Velusamy 0 0      S P 1   1 1    good - ve
12 Papathi 0 0      M A    1 1    good - ve
13 Pattamuthu 0 0      S P    1 1    good - ve
14 Sathish kumar 0 0      M A   1 1 1    good - ve
15 Raj konar 1 1 1 0 0 0 0 0 A      1 1 1 recurrence 3+ 
16 Andichi 0 0      S     A   1 1 1    good - ve
17 Arumugam 0 0      S A    1 1    Exa. > 12 wks - ve
18 Kottaisamy 0 0 0 0 0 0 0 0 A      1 1  recurrence 4+ 
19 Gopi 0 0 0 0 0 0 1 S P      1  1 Exa. > 12 wks 4+ 
20 Fathima 1 0      M A         good - ve
21 Balakrishnan 0 0      S P 1   1 1    good - ve
22 Nagaraj 0 0      0 A    1 1    good - ve
23 Hariharan 1 0      M     P    1 1    good 4+ 
24 Selvi 0 0 0 0 0 0 0 0 A      1 1  good 3+ 
25 Pandiammal 0 1 0 0 0 0 0 M A      1 1 1 good 4+ 
26 Bose 0 0 1 0 0 0 0 0 A      1 1 1 good 2+ 
27 Panju 0 0      S A    1 1    Exa. <12 wks - ve
28 Sayeed 1 0      M P    1 1    Exa. <12 wks - ve
29 Papu 0 1      M A    1 1    good - ve
30 Selvi 0 0 0 0 0 0 0 0 A      1 1 1 good 4+ 
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x 
31 Syed Ahmed 0 1 0 0 0 0 0 M P      1 1 1 good 5+ 
32 Ebinezar 0 0      S P    1 1    good 1+ 
33 Balasubramanian 1 0      S P     1 1   good - ve
34 Mookan 1 0 1     S P    1 1    good 1+ 
35 Abdul majid 1 0 0 0 0 0 0  A      1 1 1 Exa. > 12 wks 6+ 
36 Vasanthi 1 1 0 0 0 0 0 M P      1 1 1 good 6+ 
37 Shankar 1 0 0 1 0 1 1  A      1  1 good 4+ 
38 Balakrishnan 0 0 1     S P     1 1   good - ve
39 Marimuthu 1 0       A    1 1    good - ve
40 Chetty 1 0      M P         good - ve
41 Jeyamani 1 1      S A    1 1    good - ve
42 Karuthammal 1 1 0 0 0 0 0 0 A      1   good 4+ 
43 Parvathi 1 1 1 0 0 0 0 S A         good 1+ 
44 Palanisami 0 1 0 0 0 0 0 0 A      1 1 1 Exa. <12 wks 4+ 
45 Sundar 0 1      M P    1 1    good - ve
46 Ponraj 1 0      M P  1       good - ve
47 Kumar 0 1      M P 1 1       Exa. <12 wks - ve
48 Murugesan 1 0      S A    1 1    good - ve
49 Muthupandi 0 1      0 A    1 1    good 2+ 
50 Velu 0 0      0 A    1 1    good - ve
51 Sivakumar 0 0      S P         good - ve
52 Saviriraj 0 1 0 0 0 0 1 0 A      1 1 1 good 3+ 
53 Ganesan 1 1 1 0 1 1 1 M P       1 1 Exa. <12 wks 2+ 
54 Sivaraj 1 1 0 0 0 0 0 S A       1  good 4+ 
55 Stalin 0 1 0 0 1 1 0 S A      1 1  good 4+ 
56 Chinnasamy 1 0 0 0 0 0 0 M P      1 1  good 4+ 
57 Manimaran 0 1 0 0 0 0 0 M A      1 1  good 4+ 
58 Moorthi  0 0      S P  1       good - ve
59 Kumar  0 0      S P  1       good - ve
60 Muthu 0 0      S A    1 1    good - ve
61 Malliga  0 0      S P         good - ve
62 Madurai veeran 0 0      S P    1 1    good - ve
63 Chella pandi 0 0      S P  1       good - ve
 
                                                 
 
 
     CODE FOR MASTER CHART 
 TYPE OF REACTION      
           1 – Type 1 reaction 
           2 – Type 2 reaction 
 TYPE OF LEPROSY 
          1 -  BT     
          2 – BB 
          3 – BL         
          4 – LL 
          5 – Histoid Hansen 
Ppt – Precipitating factors 
Const. – Constitutional symptoms 
NEURITIS 
            S – Single nerve involvement 
           M – Multiple nerve involvement 
SENSORY IMPAIREMENT 
          P – Present 
          A – Absent 
IN ALL OTHER COULMNS 
           1 – Present 
           0 – Absent  
Exa – Exacerbation  
Trt   - Treatment  
Bact. Index – Bacteriological index 
 
 
